PBI Builds Out Marketing, Business Development, and Operational Capabilities to Support Growth Strategy
Company adds key staff, augments infrastructure, launches new corporate logo, and plans to expand into new clinical research markets.
Seattle, WASHINGTON, JUNE 24, 2005 -- Pacific Biometrics, Inc. (OTC BB: PBME, "PBI") has unveiled a series of enhancements to its marketing and business development programs designed to broaden the Company's customer base, further improve its quality of service, and upgrade the lab's operations.
To date, PBI has typically contracted with major pharmaceutical and diagnostics companies to provide highly specialized testing in the lab's focus areas of cardiovascular disease, diabetes and metabolic syndrome, and arthritis and osteoporosis. PBI plans to grow its business by continuing to provide best-in-class service to this existing client base while also pursuing opportunities in the general lab services market, diversifying the client base with medium-sized pharmaceutical and biotech companies, and leveraging its co-marketing agreement with Quintiles to participate in large-scale and global trials.
Recent initiatives to support this strategy include:
- Addition of a new Senior Vice President of Operations, with more than 15 years' experience, including time at LabCorp, who will manage lab operations and quality control procedures
- Hire of a new Controller, with more than 25 years' experience in accounting and controller positions, who will oversee development of effective cost-accounting procedures
- Installation of a new Laboratory Information System (LIS) to streamline and upgrade the Company's project and data management systems
- Adoption of a new corporate visual identity to span across all company marketing collateral and advertisements.
- Increased visibility at industry trade shows, such as the Drug Information Association (DIA) annual meeting, and in industry publications via print advertising and targeted publicity campaigns. Recent publicity for PBI includes articles in Med Ad News, B to B Business, Specialty Pharma, and Biotechnology Healthcare.
"We see significant opportunities in the clinical research space both in specialized testing and in general lab services," said Ron Helm, CEO of PBI. "Our deep expertise in three high-growth fields -- cardiovascular disease, diabetes and metabolic disease, and osteoporosis and arthritis -- along with our well established client relationships with leading pharmaceutical and diagnostic developers and our marketing relationship with Quintiles make us uniquely qualified to pursue these opportunities."
About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists and through its non-profit affiliate Pacific Biometrics Research Foundation is one of only three U.S.-based laboratories approved and accredited by the Center for Disease Control (CDC) as a Cholesterol Reference Laboratory. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.
Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.
For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com or contact Ronald Helm, Chairman / CEO at 206-298-0068.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
